Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 12/20 | 0.34 |
| ▸ | BRAF | P15056 | 12/20 | 0.34 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.32 |
| ▸ | ABL1 | P00519 | 4/20 | 0.32 |
| ▸ | EIF2S1 | P05198 | 1/20 | 0.30 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3197187 | 0.89 | RAF1 (0.34) | RAF1BRAFDDR2ABL1 | |
| SCHEMBL243872 | 0.88 | RAF1 (0.34) | RAF1BRAFDDR2ABL1 | |
| SCHEMBL3214407 | 0.88 | RAF1 (0.35) | RAF1BRAF | |
| SCHEMBL3220838 | 0.86 | RAF1 (0.33) | RAF1BRAF | |
| SCHEMBL3197206 | 0.85 | RAF1 (0.42) | RAF1BRAFABL1 | |
| SCHEMBL3208269 | 0.81 | RAF1 (0.37) | RAF1BRAF | |
| SCHEMBL3206400 | 0.79 | RAF1 (0.35) | RAF1BRAFABL1 | |
| SCHEMBL3195837 | 0.79 | ABL1 (0.32) | RAF1ABL1 | |
| SCHEMBL3219188 | 0.77 | RAF1 (0.34) | RAF1BRAFDDR2ABL1 | |
| SCHEMBL3209299 | 0.76 | MAPK14 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | RAF1 74/4885BRAF 79/4885DDR2 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.